Post by
1hot-techwoman on Mar 29, 2022 8:19am
Looking forward to upcoming Q4 !! Profitable????
Management Commentary Q3
At the start of the third quarter of 2021, significant changes were made to focus VIVO's strategy on the medical cannabis segment in Canada, Australia and Germany, and to fully leverage the efforts and investments the Company has made in medical cannabis in these geographies over the years. We expect that shareholders and patients alike will be pleased as the business becomes more focused on medical products, services and profitability. The Company has many assets and capabilities that position it as a strong player in the medical cannabis market. By developing these assets, the Company intends to establish itself as a global medical leader focused on enhancing the lives of its patients.
Business Overview
In Q3 2021, VIVO began to focus on leveraging its assets to create value in the medical cannabis segment in Canada, Australia and Germany. VIVO believes that leveraging these assets will generate long-term shareholder value and accelerate its path to profitability.
Australia, Germany and other International Markets
VIVO continues to make headway with its international expansion strategy, leveraging its experience and leadership to enter new high-growth markets. The Company's initial focus is on the German and Australian markets, which, combined, have a population of over 100 million people.
The Company currently has a strong medical brand established in Australia and leverages its Canadian knowledge base to accelerate product efficacy, cannabis medical information sharing, and sales growth in that market. With the Company's recent EU-GMP certification, it is now in a position to repeat its Australian success in Germany and in other global markets, all of which are exclusively medically focused. The Company's products and brands prove their value in Canada first, and this success is then replicated in international markets, as regulations allow.
Bring on Q4 :)